DAP Health has received the new twice-yearly injection for HIV prevention. Here's what you need to know if you're interested ...

Researchers found that lenacapavir reduced almost 100% reduction new HIV infections among participants who received it as a ...

The World Health Organization is now recommending that countries include an HIV drug newly approved for prevention as a tool ...

The FDA has approved a twice-yearly injection for HIV prevention following a groundbreaking clinical trial. Years before the ...

The $400 million that the United States Congress removed from a list of programmes from which the Trump administration wants ...

Unfortunately, the Trump administration and the Republican majorities in Congress are putting access to lifesaving ...

Lenacapavir, a long-acting injectable pre-exposure prophylaxis, has been recommended by the WHO to help protect high-risk ...

Yeztugo, a twice yearly injection, offers a promising advancement in HIV prevention, but high costs and insurance uncertainties may limit its accessibility.

Although Uganda participated in a groundbreaking trial for Lenacapavir—an injectable drug proven effective in preventing ...

As expected, the new recommendations that the World Health Organization (WHO) issued for HIV and sexually transmitted ...

WHO endorses biannual injectable Lenacapavir for HIV prevention. This long-acting PrEP offers hope for high-risk groups and ...

Kenya is set to roll out the long-acting injectable HIV Pre-Exposure prophylaxis (PrEP) Lenacapavir by January 2026 following ...